PFE Stock Analysis — Pfizer Inc.
Sector: Healthcare
AI Verdict
Pfizer trades at 9.0x next year's earnings with triple-digit EPS growth expected — that's cheap for the growth you're getting if its patent and pipeline moat delivers.
Competitive Moat
Pfizer's moat comes from its vast patent portfolio and global scale in drug development, allowing it to fund large clinical trials and navigate regulatory hurdles that smaller firms cannot. Its established distribution channels and regulatory expertise create high barriers to entry for competitors.
Summary
Pfizer's forward P/E of 9.0x and expected 114.3% EPS growth make it a rare big pharma name with deep value signals and a potential earnings rebound.
Where It Stands
Pfizer is up 10.95% over the past year, trades at 9.0x next year's earnings (well below the healthcare median of 22x), and its RSI of 31.1 signals oversold territory.
Key Metrics
- RSI: 31.1 — Near Oversold
- Trailing P/E: 19.4x
- Forward P/E: 9.0x
- PEG Ratio: 0.17
- Earnings Growth: +1.1%
- Revenue Growth: +0.0%
- Market Cap: $144.4B
- Dividend Yield: 0.07%
- 1-Year Return: 10.95%
- 52-Week High: $28.75
- 52-Week Low: $22.09
Analyst Consensus
16 Buy · 17 Hold · 3 Sell (36 analysts) · Target $26.00
Bull Case
With analysts forecasting 114.3% EPS growth and a forward P/E of just 9.0x, you're paying a bargain price for a major earnings recovery if it materializes.
Bear Case
If the P/E multiple reverts even lower or the RSI bounce fails, a move to sector median valuation would actually imply upside, but any earnings miss could see the stock languish at these depressed multiples.
Catalyst to Watch
Watch for upcoming drug trial results or regulatory approvals, as a positive outcome could rapidly close the gap between current valuation and sector norms.